Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes

Abstract

Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies.

Keywords: cardiomyocyte contraction; cardiotoxicity; human-induced pluripotent stem cell-derived cardiomyocytes; in vitro complex models; regenerative therapies.